GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (AMEX:NNVC) » Definitions » EV-to-EBITDA

Nanoviricides (Nanoviricides) EV-to-EBITDA

: -0.98 (As of Today)
View and export this data going back to 2005. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nanoviricides's enterprise value is $8.37 Mil. Nanoviricides's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.55 Mil. Therefore, Nanoviricides's EV-to-EBITDA for today is -0.98.

The historical rank and industry rank for Nanoviricides's EV-to-EBITDA or its related term are showing as below:

NNVC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6034093.58   Med: 0   Max: 24646755.18
Current: -0.98

During the past 13 years, the highest EV-to-EBITDA of Nanoviricides was 24646755.18. The lowest was -6034093.58. And the median was 0.00.

NNVC's EV-to-EBITDA is ranked worse than
100% of 469 companies
in the Biotechnology industry
Industry Median: 9.16 vs NNVC: -0.98

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Nanoviricides's stock price is $1.10. Nanoviricides's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.810. Therefore, Nanoviricides's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Nanoviricides EV-to-EBITDA Historical Data

The historical data trend for Nanoviricides's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => -2.06 [6] => -4.38 [7] => -4.11 [8] => -1.06 [9] => -0.68 )
Nanoviricides Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.06 -4.38 -4.11 -1.06 -0.68

Nanoviricides Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.66 -0.68 -1.25 -0.79

Competitive Comparison

For the Biotechnology subindustry, Nanoviricides's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoviricides EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Nanoviricides's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nanoviricides's EV-to-EBITDA falls into.



Nanoviricides EV-to-EBITDA Calculation

Nanoviricides's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=8.371/-8.55
=-0.98

Nanoviricides's current Enterprise Value is $8.37 Mil.
Nanoviricides's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanoviricides  (AMEX:NNVC) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Nanoviricides's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.10/-0.810
=At Loss

Nanoviricides's share price for today is $1.10.
Nanoviricides's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.810.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Nanoviricides EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Nanoviricides's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoviricides (Nanoviricides) Business Description

Traded in Other Exchanges
Address
1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Executives
Makarand Jawadakar director C.O NANOVIRICIDES, INC, 1 CONTROLS DRIVE, SHELTON CT 06484
Mark D. Day director C/O NANOVIRICIDES, INC., 1 CONTROLS DRIVE, SHELTON CT 06484
Milton Boniuk director C/O NANOVIRICIDES, INC., 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Anil Diwan director, 10 percent owner, officer: President 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Mukund S Kulkarni director C/O NANOVIRICIDES, INC., 135 WOOD ST, SUITE 205, WEST HAVEN CT 06516
Meeta Vyas officer: Chief Financial Officer 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Eugene Seymour director, 10 percent owner 666 THIRD AVENUE, NEW YORK NY 10017
Theracour Pharma, Inc. 10 percent owner 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516

Nanoviricides (Nanoviricides) Headlines